<DOC>
	<DOCNO>NCT00567840</DOCNO>
	<brief_summary>The trial evaluate extend bactericidal activity 14 consecutive day oral administration PA-824 200 , 600 , 1000 1200 mg per day adult patient newly diagnose , uncomplicated , smear positive tuberculosis . A control group receive standard TB treatment .</brief_summary>
	<brief_title>PA-824-CL-007 : Phase IIa Evaluation Early Bactericidal Activity Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<criteria>informed consent M/F 1864 yo newly diagnose pulmonary TB sputum positive adequate contraception poor health rifampicin resistance treatment anti TB agent last 3 mo . extrapulmonary TB COPD neuropathy ECG wih QRS prolongation ove 120 msec CV disorder diabetes require insulin Metabolic disease drug/alcohol abuse pregnancy use substance strong inhibitors/inducers CYP450 use ARV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Early Bactericidal Activity</keyword>
	<keyword>EBA</keyword>
	<keyword>pulmonary tuberculosis</keyword>
	<keyword>PA-824</keyword>
	<keyword>Pretomanid</keyword>
	<keyword>CL-007</keyword>
</DOC>